Cotinga Pharmaceuticals Inc COTQF

Healthcare Biotechnology

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

GREY:COTQF - Post by User

Cotinga Pharmaceuticals Inc > Silva has to go

<< Previous

Bullboard Posts

Next >>

Comment by PROtradingon Jun 06, 2017 5:28pm

153 Views

Post# 26332240

RE:RE:Silva has to go

Let me translate: you are a long time bagholder! LMAO!!!! This junk is trading at 52 week lows and looking that the financials they hasd NEGATIVE $1.14M cash flow!!!

Krap picker20122, why do you do this to yourself. That really seems really dumb!!!

You can't be an investor, you'd be running out of money! Who pays you to pump this junk?

Kipk20122 wrote:
I am a long time investor here. Got in during their 2nd offerings. Have meet Alison and talked to her several time. She knows her stuff and she knows a lot of people. Trials are on going, bit slower than I hoped, But are progressing. Yes, I was taken back with Dr. Cantor issue as I really like him. But, like anything else, there was a time for a different skill set and that what Silvia came in. I had hope we could have maintained Dr. Cantor at some capacity, but life goes on and we have to just hold on. The P53 story is very powerful & hope both patients & investor benefit from it.

<< Previous

Bullboard Posts

Next >>

Silvercorp to expand into Ecuador with C$200M Adventus acquisition